OMERS ADMINISTRATION Corp Takes Position in Monopar Therapeutics Inc. $MNPR

Key Points

• OMERS ADMINISTRATION Corp purchased 9,000 shares of Monopar Therapeutics valued at approximately $328,000, increasing its stake to about 0.15% in the company.
• Multiple institutional investors, including JPMorgan Chase and Janus Henderson Group, have also recently acquired new positions in Monopar Therapeutics, indicating growing interest in the company.
• Analysts have given Monopar Therapeutics an average rating of "Buy," with price targets ranging from $60.00 to $77.00, reflecting positive sentiment about the company's future performance.

OMERS ADMINISTRATION Corp purchased a new position in Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 9,000 shares of the company's stock, valued at approximately $328,000. OMERS ADMINISTRATION Corp owned about 0.15% of Monopar Therapeutics as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in MNPR. AlphaQuest LLC bought a new stake in shares of Monopar Therapeutics during the 1st quarter valued at about $44,000. JPMorgan Chase & Co. purchased a new position in Monopar Therapeutics during the 4th quarter valued at about $45,000. Gerber LLC purchased a new position in Monopar Therapeutics in the first quarter worth about $204,000. Affinity Asset Advisors LLC purchased a new position in Monopar Therapeutics in the first quarter worth about $2,257,000. Finally, Point72 Asset Management L.P. purchased a new position in Monopar Therapeutics in the fourth quarter worth about $3,694,000. Institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Trading Up 13.8%

NASDAQ MNPR traded up $5.37 during trading hours on Friday, hitting $44.21. 34,621 shares of the company's stock traded hands, compared to its average volume of 37,063. The business's fifty day moving average price is $38.33 and its two-hundred day moving average price is $36.60. The firm has a market capitalization of $272.78 million, a P/E ratio of -13.28 and a beta of 1.20. Monopar Therapeutics Inc. has a 52 week low of $2.29 and a 52 week high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.12. On average, sell-side analysts expect that Monopar Therapeutics Inc. will post -1.65 EPS for the current fiscal year.

Insider Activity

In other news, CEO Chandler Robinson sold 16,800 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the sale, the chief executive officer owned 73,472 shares of the company's stock, valued at approximately $2,938,880. This represents a 18.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Christopher M. Starr sold 16,800 shares of the company's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the transaction, the director owned 5,173 shares in the company, valued at approximately $206,920. The trade was a 76.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,504 shares of company stock valued at $1,700,160. 20.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

MNPR has been the subject of several recent analyst reports. HC Wainwright initiated coverage on shares of Monopar Therapeutics in a report on Tuesday, August 26th. They issued a "buy" rating and a $70.00 target price for the company. Wall Street Zen raised shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Oppenheimer assumed coverage on shares of Monopar Therapeutics in a report on Wednesday. They set an "outperform" rating and a $77.00 price objective for the company. Raymond James Financial assumed coverage on shares of Monopar Therapeutics in a report on Tuesday. They set a "strong-buy" rating and a $80.00 price objective for the company. Finally, Chardan Capital reissued a "buy" rating and set a $60.00 price objective on shares of Monopar Therapeutics in a report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $69.57.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.